Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Merck
Dow
Moodys
Colorcon

Last Updated: May 29, 2023

XARACOLL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Xaracoll patents expire, and when can generic versions of Xaracoll launch?

Xaracoll is a drug marketed by Innocoll Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-six patent family members in fifteen countries.

The generic ingredient in XARACOLL is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.

Summary for XARACOLL
International Patents:26
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 123
Clinical Trials: 4
Patent Applications: 4,320
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in XARACOLL?XARACOLL excipients list
DailyMed Link:XARACOLL at DailyMed
Drug patent expirations by year for XARACOLL
Recent Clinical Trials for XARACOLL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Premier Research Group plcPhase 3
CmedPhase 3
InnocollPhase 3

See all XARACOLL clinical trials

Pharmacology for XARACOLL
Drug ClassAmide Local Anesthetic
Physiological EffectLocal Anesthesia
Anatomical Therapeutic Chemical (ATC) Classes for XARACOLL

US Patents and Regulatory Information for XARACOLL

XARACOLL is protected by one US patents and one FDA Regulatory Exclusivity.

Patents protecting XARACOLL

Drug delivery device for providing local analgesia, local anesthesia or nerve blockage
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION

FDA Regulatory Exclusivity protecting XARACOLL

NEW PRODUCT
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Innocoll Pharms XARACOLL bupivacaine hydrochloride IMPLANT;IMPLANTATION 209511-001 Aug 28, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Innocoll Pharms XARACOLL bupivacaine hydrochloride IMPLANT;IMPLANTATION 209511-001 Aug 28, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Merck
Johnson and Johnson
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.